|
Author(s) |
Joseph, L. J.; Bhartiya, U. S.; Raut, Y. S.; Hawaldar, R. W.; Nayak, Y.; Pawar, Y. P.; Jambhekar, N. A.; Rajan, M. G. R.
|
Source |
Cancer Biotherapy and Radiopharmaceuticals, 2011. Vol. 26 (6): pp. 737-743 |
ABSTRACT
|
The current study investigated the radioprotective effect of Ocimum sanctum on the salivary gland of rats administered radioiodine (131I) and compared its efficacy with a known radioprotectant, amifostine. The experimental rats were divided in four groups and sacrificed in three different batches at 1, 3, and 6 months of time interval after 18.5 MBq/100g (i.p.) 131I exposure. Six months duration batch received 131I exposure twice with the gap of 3 months. Two groups of experimental rats were presupplemented with O. sanctum (40mg/kg for 5 days, orally) and amifostine (200 mg/kg, s.c) before 131I exposure separately. Increased Technetium-99m-pertechnetate (99mTcO4- ) uptake at 30 minutes post injection in salivary glands of only 131I exposed rats may imply delay in clearance at 6 months of exposure in comparison to their counterparts sacrificed at 1 month. Parotid gland histology showed atrophy with lipomatosis in only 131I exposed rats at 3 and 6 months of duration. O. sanctum and amifostine presupplemented and subsequently exposed to 131I rats at 3 and 6 months duration exhibited comparable histopathology with controls. Our study indicates possible radioprotective effect of O. sanctum and amifostine against high-dose 131I exposure. |
|
|
|